Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Heather Ball

Physician Assistant Roanoke, VA Physician Assistant

NPI 1063661049 CMS profile 11241395

4910 Valley View Blvd Nw, Roanoke, VA 24012

Open in the dashboard

General payments

$7,372

433 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Heather Ball of Roanoke, VA is reported in the CMS Open Payments database as having received $7,372 across 433 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,175 62
2024 General $1,335 79
2023 General $2,321 128
2022 General $1,429 94
2021 General $1,112 70

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Heather Ball
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Heather Ball were reported at $1,175. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Heather Ball Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $1,112 $132 $37–$438 $132
2022 $1,429 $155 $48–$522 $149
2023 $2,321 $167 $52–$557 $160
2024 $1,335 $178 $55–$600 $164
2025 $1,175 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Novo Nordisk Inc $1,517 79 payments
  2. AbbVie, Inc. $843 49 payments
  3. Lilly USA, LLC $805 76 payments
  4. Pfizer Inc. $527 37 payments
  5. Otsuka America Pharmaceutical, Inc. $496 23 payments
  6. Amgen Inc. $402 25 payments
  7. Abbott Laboratories $354 24 payments
  8. AstraZeneca Pharmaceuticals LP $346 15 payments
  9. Salix Pharmaceuticals, a division of Bausch Health US, LLC $238 13 payments
  10. Merck Sharp & Dohme Corporation $200 8 payments
  11. Other $1,644 84 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $7,372 433 payments
Products named General payments · program years 2021–2025
  1. Ozempic $968 52 payments
  2. RYBELSUS $916 50 payments
  3. REXULTI $496 23 payments
  4. MOUNJARO $461 50 payments
  5. Wegovy $434 20 payments
  6. UBRELVY $387 19 payments
  7. NURTEC ODT $290 22 payments
  8. JARDIANCE $284 21 payments
  9. QULIPTA $275 14 payments
  10. EVENITY $266 16 payments
  11. Other $5,659 329 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 135 drugs

Part D claims

7,933

Median for Physician Assistant: 241

Drug cost

$450,077

Median for Physician Assistant: $4,110

Branded share of claims

22%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 59 $69,986
Jardiance Empagliflozin Brand 87 $69,769
Ozempic Semaglutide Brand 28 $44,181
Mounjaro Tirzepatide Brand 43 $44,002
Farxiga Dapagliflozin Propanediol Brand 27 $28,167
Januvia Sitagliptin Phosphate Brand 24 $21,917
Linzess Linaclotide Brand 19 $20,617
Rybelsus Semaglutide Brand 11 $19,183
Xarelto Rivaroxaban Brand 16 $14,475
Toujeo Solostar Insulin Glargine,hum.Rec.Anlog Brand 13 $11,081

The 10 drugs with the highest cost, of 135 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 57 billing codes

Paid by Medicare

$85,705

Of which drugs: $25,948

Medicare patients

280

Average age 74

Services billed

2,461

203 women, 77 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 73%
Arthritis 42%
Diabetes 28%
Atrial fibrillation 18%
Depression 18%
Ischemic heart disease 17%
Chronic kidney disease 16%
Heart failure 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Pcv20 vaccine im 90677 Office 14 14 $4,080
Vaccine for influenza for injection into muscle 90653 Office 36 36 $2,946

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 27 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
REXULTI
  • Otsuka America Pharmaceutical, Inc. $166
$166 — —
RYBELSUS
  • Novo Nordisk Inc $121
$121 11 —
Ozempic
  • Novo Nordisk Inc $121
$121 28 —
MOUNJARO
  • Lilly USA, LLC $86
$86 43 —
Wegovy
  • Novo Nordisk Inc $80
$80 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 27 with Patron

Records

433 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record